The crucial role of spacer groups in macromolecular prodrug design
- 1 September 1996
- journal article
- review article
- Published by Elsevier in Advanced Drug Delivery Reviews
- Vol. 21 (2) , 81-106
- https://doi.org/10.1016/s0169-409x(96)00400-0
Abstract
No abstract availableKeywords
This publication has 86 references indexed in Scilit:
- On the size of the active site in proteases. I. PapainPublished by Elsevier ,2005
- Prodrugs in cancer chemotherapyThe International Journal of Cell Cloning, 1995
- Influence of molecular weight on passive tumour accumulation of a soluble macromolecular drug carrierEuropean Journal Of Cancer, 1995
- Hybridoma cells producing antibodies to cathepsin L have greatly reduced potential for tumour growthZeitschrift für Krebsforschung und Klinische Onkologie, 1994
- Plasmin-activated prodrugs for cancer chemotherapy. 2. Synthesis and biological activity of peptidyl derivatives of doxorubicinJournal of Medicinal Chemistry, 1983
- Cis-aconityl spacer between daunomycin and macromolecular carriers: A model of pH-sensitive linkage releasing drug from a lysosomotropic conjugateBiochemical and Biophysical Research Communications, 1981
- Action of cathepsin L on the oxidized B‐chain of bovine insulinFEBS Letters, 1980
- Degradation of side chains of N-(2 hydroxypropyl) methacrylamide copolymers by lysosomal enzymesBiochemical and Biophysical Research Communications, 1980
- Inhibition of cathepsin D by diazoacetylnorleucine methyl esterFEBS Letters, 1970
- On proteins. CXIII. Specificity of cleavage of heptapeptide substrate with bovine spleen cathepsin DCollection of Czechoslovak Chemical Communications, 1968